How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?

Autor: Vickers AJ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: vickersa@mskcc.org., Russo G; Urology Section, University of Catania, Catania, Italy., Lilja H; Departments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Evans C; Department of Urology, School of Medicine, University of California, Davis, Sacramento, CA, USA., Schalken JA; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Klein E; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA., Eggener S; Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, IL, USA.
Jazyk: angličtina
Zdroj: European urology oncology [Eur Urol Oncol] 2022 Apr; Vol. 5 (2), pp. 135-137. Date of Electronic Publication: 2021 Feb 16.
DOI: 10.1016/j.euo.2021.01.010
Abstrakt: The literature gives limited data or guidance on how to select or combine biomarkers and magnetic resonance imaging (MRI) for the early detection of prostate cancer. We strongly recommend prospective studies large enough to address questions such as the properties of biomarkers in cases with high versus low Prostate Imaging-Reporting and Data System scores or the correlation between biomarkers and MRI, and that evaluate results in the context of reasonable clinical scenarios.
(Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: